News | July 17, 2024
Lupin divests US commercial women's health specialty business to Evofem
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The facility is a part of Lupin Manufacturing Solutions
The Unit has been issued GMP Certification from ANVISA-Brazil
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Subscribe To Our Newsletter & Stay Updated
